Abstract: Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.

Abstract: Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.

Abstract: Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include amyloid beta (A?), and the methods, agents and devices are useful for reducing the accumulation of A?, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A?, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral antibodies to A?, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Abstract: Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include amyloid beta (A?), and the methods, agents and devices are useful for reducing the accumulation of A?, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A?, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral antibodies to A?, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Abstract: Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include A?, and the methods, agents and devices are useful for reducing the accumulation of A?, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A?, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral of antibodies to A?, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Abstract: The present invention is directed to compositions, methods and kits for regulation of gene therapies for Huntington's Disease, including, without limitation, reversible gene therapies and allele-specific therapies.

Abstract: The instant invention provides a method for improving efficiency of RNA delivery to cells. The method comprises applying a low strength electric field to the cells and then after a certain time period, administering the ribonucleic acid sequence to the cells. Devices, kits, and RNA molecules suitable for delivery and devices suitable for practicing the disclosed methods are also provided.

Abstract: The invention provides novel combination therapies for treating Huntington's disease which comprise a) BDNF or suitable fragments thereof and b) agents capable of causing inhibition of a gene responsible for the neurodegenerative disease. The invention provides nucleic acid sequences, methods, and systems suitable for applications of these combination therapies.

Abstract: Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.

Abstract: The instant invention provides a method for improving efficiency of RNA delivery to cells. The method comprises applying a low strength electric field to the cells and then after a certain time period, administering the ribonucleic acid sequence to the cells. Devices, kits, and RNA molecules suitable for delivery and devices suitable for practicing the disclosed methods are also provided.

Abstract: The instant invention provides a method for improving efficiency of RNA delivery to cells. The method comprises applying a low strength electric field to the cells and then after a certain time period, administering the ribonucleic acid sequence to the cells. Devices, kits, and RNA molecules suitable for delivery and devices suitable for practicing the disclosed methods are also provided.

Abstract: The present invention is directed to compositions, methods and kits for regulation of gene therapies for Huntington's Disease, including, without limitation, reversible gene therapies and allele-specific therapies.

Abstract: The invention provides novel combination therapies for treating Huntington's disease which comprise a) BDNF or suitable fragments thereof and b) agents capable of causing inhibition of a gene responsible for the neurodegenerative disease. The invention provides nucleic acid sequences, methods, and systems suitable for applications of these combination therapies.

Abstract: A system includes (i) a medium having a solid support to which an antibody directed to target molecule is bound, (ii) a reservoir for containing the medium, (iii) a first catheter, and (iv) a second catheter. The first catheter has a proximal end portion, an opening for removal of cerebrospinal fluid from a subject, and a lumen extending from the proximal end portion to the opening. The first catheter is operably couplable to the reservoir such that fluid is capable of flowing from the lumen to the reservoir. The second catheter has a proximal end portion, a delivery region for returning cerebrospinal fluid to the subject, and a lumen extending from the proximal end portion to the delivery region. The second catheter is operably couplable to the reservoir such that fluid is capable of flowing from the reservoir to the lumen.

Abstract: Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include A?, and the methods, agents and devices are useful for reducing the accumulation of A?, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A?, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral of antibodies to A?, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Abstract: Liposome complexes are provided for site-specific delivery of pharmaceutical agents with improved targeting efficiency. The liposome complexes include a pharmaceutical agent associated with the liposome; a sialic acid-containing molecule associated with the liposome; and optionally a targeting agent attached to the sialic acid-containing molecule. The invention also provides methods of making liposome complexes and their in vivo administration.